Status:
UNKNOWN
Copeptin and Nonalcoholic Fatty Liver Disease
Lead Sponsor:
University of Colorado, Denver
Conditions:
NAFLD
Eligibility:
All Genders
30-75 years
Brief Summary
Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver dis...
Detailed Description
Participants: As a pilot study, the investigators will recruit 30 obese adults with NAFLD based upon ultrasound echogenicity within 6 months of enrollment, and 30 obese adults without NAFLD based upon...
Eligibility Criteria
Inclusion
- Patients age 30-75
- BMI 30-40
- Presence of fatty liver on ultrasound
Exclusion
- Diabetes mellitus (determined by prior HbA1c, fasting glucose, and/or random glucose in the last three months according to ADA criteria),
- Medication known to affect insulin sensitivity e.g. metformin, thiazolidinediones, systemic steroids, atypical antipsychotics),
- Fibrates,
- eGFR \<45 ml/min/1.73m2 by MDRD equation(11),
- Pregnancy,
- Breast feeding,
- Sodium \<135 mEq/L,
- Diabetes insipidus,
- Liver disease other than NAFLD (including obstructive liver disease),
- ALT or AST\>60 IU/L,
- Hepatic steatosis on ultrasound for the non-NAFLD group,
- Congestive heart failure,
- Patients who consume \>20g of ETOH a day,
- Patients found to have Cushing's disease based upon 24 hour urine results (Urine Free cortisol \>2x upper limit of normal).
- Patient's with pacemakers
- Off of Coenzyme Q for 6 months.
Key Trial Info
Start Date :
June 19 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03254563
Start Date
June 19 2018
End Date
June 1 2021
Last Update
February 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado
Aurora, Colorado, United States, 80045